Combined Inositol Hexakisphosphate and Inositol Supplement Consumption Improves Serum Alpha-Amylase Activity and Hematological Parameters in Streptozotocin-Induced Type 2 Diabetic Rats

Table 3

Complete blood count analysis of diabetic rats treated with combined IP6 and inositol supplement or glibenclamide.

Hematology	NC	HFC	DC	IP6 + INO	Glib
WBC (10^3/uL)	12.9 ± 0.24^a	13.42 ± 1.7^a	9.61 ± 1.27^a	10.3 ± 0.64^a	9.7 ± 1.45^a
RBC (10^6/uL)	9.45 ± 0.2^a	9.37 ± 0.3^a	8.95 ± 0.20^a	9.71 ± 0.13^a	9.38 ± 0.2^a
Hemoglobin (g/dL)	17.23 ± 0.3^a	17.23 ± 0.4^a	16.6 ± 0.2^a	17.62 ± 0.3^a	17.1 ± 0.47^a
Hematocrit (%)	51.13 ± 0.3^a	51.15 ± 1.6^a	49.8 ± 0.6^a	53.32 ± 0.6^a	51.8 ± 1.52^a
MCV (fL)	54.1 ± 0.64^a	54.68 ± 1.0^a	55.8 ± 0.63^a	54.9 ± 0.23^a	55.3 ± 0.44^a
MCH (pg)	18.27 ± 0.1^a	18.4 ± 0.42^a	18.6 ± 0.29^a	18.16 ± 0.2^a	18.2 ± 0.11^a
MCHC (g/dL)	33.73 ± 0.1^a	33.6 ± 0.34^a	33.4 ± 0.18^a	33.06 ± 0.3^a	33.1 ± 0.23^a
CHCM (g/dL)	33.6 ± 0.9^a	33.6 ± 0.4^a	33.4 ± 0.3^a	32.8 ± 0.3^a	32.8 ± 0.25^a
RDW (%)	11.9 ± 0.15^a	12 ± 0.91^a	12.9 ± 0.14^b	12.4 ± 0.17^a	12.3 ± 0.21^a
HDW (g/dL)	2.8 ± 0.02^a	2.8 ± 0.03^a	2.7 ± 0.06^a	2.7 ± 0.05^a	2.61 ± 0.05^a
PLT (10^3/uL)	582 ± 143^a	673 ± 116^a	637 ± 59.5^a	681 ± 42.2^a	685 ± 83.2^a
MPV (fL)	6.7 ± 0.09^a	6.4 ± 0.15^a	6.7 ± 0.15^a	6.9 ± 0.17^a	6.7 ± 0.17^a

Note. Data are shown as mean ± S.E.M (n = 6). The mean values in a row with different superscript letters are significantly different at , as assessed by Duncan’s multiple range test. NC, normal control; HFC, high-fat control; DC, diabetic untreated control; IP6 + INO, combined IP6 and inositol; RDW, red cell distribution of width, HDW, hemoglobin distribution width; WBC, white blood cell; RBC, red blood cell; HGB, hemoglobin; HCT, haematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; CHCM, cell hemoglobin concentration mean; MPV, mean platelet volume; PLT, platelet count.